Results from 2 meta-analyses including 52 prospective trials involving patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) showed that weekly low-dose schedules of chemoradiotherapy produce comparable survival outcomes and response rates as the standard 3-weekly schedule.
“This paper [Szturz et al] is nice because it brings all the data together, but still doesn’t substitute for prospective, randomized studies. When we see those data, it doesn’t look like the weekly is the better way to go and there’s some indicators it may be the worse way to go.”
Szturz P, Wouters K, Kiyota N, et al. Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non- nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data [published online May 22, 2017]. Oncologist. doi: 10.1634/theoncologist.2016-0414.
... to read the full story